A Phase 3 interventional study of Cariprazine and Placebo in Bipolar Disorder and Mania, sponsored by Forest Laboratories. Completed at 28 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-04-17.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Bipolar Disorder by AbbVie — 2 open to participants now, 2 under way, none of them phase 3. Bipolar Disorder · AbbVie.
Among the 11 studies in Bipolar Disorder by AbbVie, this one is the 4th largest by enrollment, is the only one that started in 2010, is one of 3 in phase 3, and was the 4th registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →2 of the 11 studies in Bipolar Disorder by AbbVie are open now, in 1 country. Recruiting first, the newest first:
AbbVie · Sites in United States
Ages 18–65
AbbVie · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 323 is above the median of 64 across 1,280 interventional studies indexed under Bipolar Disorder.
Median enrollment 234 across the 11 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
2 of the studies in Bipolar Disorder by AbbVie that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07071532AbbVieA Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder | 2027-02 |
| NCT06696755AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Bipolar Disorder by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine monotherapy versus placebo for the treatment of acute manic or mixed episodes associated with bipolar I disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cariprazine 3 mg - 12 mg capsules oral administration, once per day for 3 weeks.
Drug: Cariprazine
Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
Drug: Placebo
Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine.
Patients who meet eligibility criteria will be administered a once daily oral dose of placebo.
Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3
The YMRS is an 11-item scale that assesses manic symptoms based on the participant's perception of his or her condition over the previous 48 hours, as well as the physician's clinical observations during the interview. The 11-items are elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, rate and amount of speech, language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight. The severity of the abnormality for 7-items are rated on a 5-point scale (0-4) and 4-items on a 9-point scale (0-8). The individual scores are summed for a total possible score of 0 (best) to 60 (worst). A negative change from Baseline indicates improvement. Analysis was a mixed model for repeated measurements (MMRM) observed cases (OC), with treatment group, pooled study center, visit, treatment group-by-visit interaction as factors, baseline value and baseline-by-visit interaction as covariates and an unstructured covariance matrix.
Time frame: Baseline, Week 3
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Total Score at Week 3
The CGI-S measures the investigator's assessment of overall severity of the participant's illness compared with the severity of illness in other patients the physician has observed using a 7-point scale (1=Normal, not ill at all to 7=Among the most extremely ill participants). A negative change from Baseline indicates improvement. Analysis was based on a MMRM using the observed cases (OC) data, with treatment group, pooled study center, visit, treatment group-by-visit interaction as factors, baseline value and baseline-by-visit interaction as covariates and an unstructured covariance matrix.
Time frame: Baseline, Week 3
| Milestone | Placebo | Cariprazine |
|---|---|---|
| Started | 154 | 158 |
| Completed | 106 | 108 |
| Not completed | 48 | 50 |
| Withdrew: Adverse event | 11 | 15 |
| Withdrew: Insufficient therapeutic response | 16 | 7 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Withdrawal of consent | 17 | 26 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Other unspecified | 2 | 0 |
| Milestone | Placebo | Cariprazine |
|---|---|---|
| Started | 133 | 134 |
| Completed | 129 | 130 |
| Not completed | 4 | 4 |
The YMRS is an 11-item scale that assesses manic symptoms based on the participant's perception of his or her condition over the previous 48 hours, as well as the physician's clinical observations during the interview. The 11-items are elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, rate and amount of speech, language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight. The severity of the abnormality for 7-items are rated on a 5-point scale (0-4) and 4-items on a 9-point scale (0-8). The individual scores are summed for a total possible score of 0 (best) to 60 (worst). A negative change from Baseline indicates improvement. Analysis was a mixed model for repeated measurements (MMRM) observed cases (OC), with treatment group, pooled study center, visit, treatment group-by-visit interaction as factors, baseline value and baseline-by-visit interaction as covariates and an unstructured covariance matrix.
| score on a scale | Placebo | Cariprazine |
|---|---|---|
| Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3 | -15.3 ± 0.9 | -19.6 ± 0.9 |
The CGI-S measures the investigator's assessment of overall severity of the participant's illness compared with the severity of illness in other patients the physician has observed using a 7-point scale (1=Normal, not ill at all to 7=Among the most extremely ill participants). A negative change from Baseline indicates improvement. Analysis was based on a MMRM using the observed cases (OC) data, with treatment group, pooled study center, visit, treatment group-by-visit interaction as factors, baseline value and baseline-by-visit interaction as covariates and an unstructured covariance matrix.
| score on a scale | Placebo | Cariprazine |
|---|---|---|
| Change From Baseline in Clinical Global Impression-Severity (CGI-S) Total Score at Week 3 | -1.3 ± 0.1 | -1.6 ± 0.1 |
Collected over First dose of study drug to 30 days past last dose (Up to 51 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 5/154 (3.2%) | 69/154 (44.8%) |
| Cariprazine | — | 6/158 (3.8%) | 110/158 (69.6%) |
| Event | Placebo | Cariprazine |
|---|---|---|
| ManiaPsychiatric disorders | 1/154 | 3/158 |
| Hepatitis EInfections and infestations | 1/154 | 0/158 |
| Social stay hospitalisationSocial circumstances | 1/154 | 0/158 |
| Bipolar disorderPsychiatric disorders | 1/154 | 0/158 |
| Non-cardiac chest painGeneral disorders | 1/154 | 0/158 |
| AkathisiaNervous system disorders | 0/154 | 1/158 |
| ConvulsionNervous system disorders | 0/154 | 1/158 |
| Suicidal ideationPsychiatric disorders | 0/154 | 1/158 |
| Event | Placebo | Cariprazine |
|---|---|---|
| AkathisiaNervous system disorders | 8/154 | 35/158 |
| Extrapyramidal DisorderNervous system disorders | 3/154 | 24/158 |
| TremorNervous system disorders | 9/154 | 19/158 |
| HeadacheNervous system disorders | 16/154 | 18/158 |
| DyspepsiaGastrointestinal disorders | 7/154 | 17/158 |
| NauseaGastrointestinal disorders | 10/154 | 16/158 |
| VomitingGastrointestinal disorders | 7/154 | 16/158 |
| ConstipationGastrointestinal disorders | 10/154 | 14/158 |
| DizzinessNervous system disorders | 6/154 | 14/158 |
| DiarrhoeaGastrointestinal disorders | 6/154 | 11/158 |
Safety Population included all randomized participants who took at least 1 dose of double-blind investigational product.
| Age, Continuous(years) | Placebo | Cariprazine | Total |
|---|---|---|---|
| Mean | 36.7 ± 11.8 | 35.8 ± 11.4 | 36.3 ± 11.5 |
| Sex: Female, Male(Participants) | Placebo | Cariprazine | Total |
|---|---|---|---|
| Female | 59 | 53 | 112 |
| Male | 95 | 105 | 200 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Cariprazine | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 5 | 10 |
| Not Hispanic or Latino | 149 | 153 | 302 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Cariprazine | Total |
|---|---|---|---|
| White | 33 | 33 | 66 |
| Black/African American | 29 | 33 | 62 |
| Asian | 88 | 91 | 179 |
| American Indian or Alaska Native | 3 | 0 | 3 |
| Other | 1 | 1 | 2 |
| Weight(kilogram (kg)) | Placebo | Cariprazine | Total |
|---|---|---|---|
| Mean | 71.86 ± 20.27 | 69.55 ± 20.06 | 70.69 ± 20.17 |
| Height(centimeter (cm)) | Placebo | Cariprazine | Total |
|---|---|---|---|
| Mean | 166.39 ± 10.64 | 165.21 ± 10.68 | 165.79 ± 10.66 |
| Body Mass Index (BMI)(kg/meter(m)^2) | Placebo | Cariprazine | Total |
|---|---|---|---|
| Mean | 25.73 ± 5.98 | 25.24 ± 5.98 | 25.48 ± 5.98 |
The record gives a start of Feb 2010, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 5 years 9 months after primary completion. A results delay was requested in Aug 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cariprazine